Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece

Applied and Environmental Microbiology

Volumn 73, Issue 21, 2007, Pages 6697-6704

  Dedepsidis, Evaggelos ^a   Kyriakopoulou, Zaharoula ^a   Pliaka, Vaia ^a   Kottaridi, Christine ^a   Bolanaki, Eugenia ^a   Levidiotou Stefanou, Stamatina ^b   Komiotis, Dimitri ^a   Markoulatos, Panayotis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHARACTERIZATION; DISEASES; GENETIC ENGINEERING; GREECE; SEWAGE; VACCINES;

GENOMIC CHARACTERIZATION; RETROSPECTIVE CHARACTERIZATION; VACCINE-DERIVED POLIOVIRUS;

VIRUSES;

POLIOMYELITIS VACCINE; SINGLE STRANDED RNA; VIRUS RNA;

AMINO ACID; DISEASE PREVALENCE; DIVERGENCE; GENOME; MOLECULAR ANALYSIS; PHENOTYPE; SEWAGE; VACCINE; VIRUS;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ARTICLE; ENTEROVIRUS; ENVIRONMENTAL FACTOR; EPIDEMIC; GENE SEQUENCE; GENE STRUCTURE; GENETIC RECOMBINATION; GREECE; HOSPITAL WASTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLIOMYELITIS VIRUS 1; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEWAGE; TEMPERATURE SENSITIVITY; VACCINE PRODUCTION; VIRUS CAPSID; VIRUS GENE; VIRUS ISOLATION;

CAPSID PROTEINS; GREECE; HUMANS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RECOMBINATION, GENETIC; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SEWAGE;

ATHENS [ATTICA]; ATTICA; EURASIA; EUROPE; GREECE; SOUTHERN EUROPE;

ENTEROVIRUS; HUMAN POLIOVIRUS 1; MIRIDAE;

EID: 35948972190     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/AEM.00535-07     Document Type: Article

References (61)

1. Abraham, R., P. D. Minor, G. Dunn, J. F. Modlin, and P. L. Ogra. 1993. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated poliovirus vaccine. J. Infect. Dis. 168:1105-1109.
2. Balanant, J., S. Guillot, A. Candrea, F. Delpeyroux, and R. Crainic. 1991. The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay. Virology 184:645-654.
3. Bellmunt, A., G. May, R. Zell, P. Pring-Akerblom, W. Verhagen, and A. Heim. 1999. Evolution of poliovirus type 1 during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265:178-184.
4. Belnap, D. M., B. M. McDermott, D. J. Filman, N. Cheng, B. L. Trus, H. J. Zuccola, V. R. Racaniello, J. M. Hogle, and A. C. Steven. 2000. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. USA 97:73-78.
5. Blomqvist. S., C. Savolainen, P. Laine, P. Hirttiö, E. Lamminsalo, E. Penttilä, S. Jöks, M. Roivainen, and T. Hovi. 2004. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J. Virol. 78:4876-4883.
6. Blomqvist, S., A. Skyttä, M. Roivainen, and T. Hovi. 1999. Rapid detection of human rhinoviruses in nasopharyngeal aspirates by a microwell reverse transcription-PCR-hybridization assay. J. Clin. Microbiol. 37:2813-2816.
7. Bouchard, M. J., D. H. Lam, and V. R. Racianello. 1995. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69:4972-4978.
8. Brown, B., M. S. Oberste, K. Maher, and M. A. Pallansch. 2003. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J. Virol. 77:8973-8984.
9. Buttinelli, G., V. Donati, S. Fiore, J. Marturano, A. Plebani, P. Balestri, A. R. Soresina, R. Vivarelli, F. Delpeyroux, J. Martin, and L. Fiore. 2003. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 84:1215-1221.
10. Cammack, N., A. Phillips, G. Dunn, V. Patel, and P. D. Minor. 1988. Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167:507-514.
11. Caro, V., S. Guillot, A. Candrea, F. Delpeyroux, and R. Crainic. 2001. Molecular strategy of 'serotyping' of human enterovirus. J. Gen. Virol. 82:79-91.
12. Casas, I., L. Powell, P. E. Klapper, and G. M. Cleator. 1995. New method for the extraction of viral RNA and DNA from cerebrospinal fluid for use in the polymerase chain reaction assay. J. Virol. Methods 53:25-36.
13. Centers for Disease Control and Prevention. 1997. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral polovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 46:1-25.
14. Centers for Disease Control and Prevention. 2006. Update on vaccine-derived polioviruses. Morb. Mortal. Wkly. Rep. 55:1093-1097.
15. Cherkasova, E. A., E. A. Korotkova, M. L. Yakovenko, O. E. Ivanova, T. P. Eremeeva, K. M. Chumakov, and V. I. Agol. 2002. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76:6791-6799.
16. Colston, E. M., and V. R. Racianello. 1994. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 13:5855-5862.
17. Dedepsidis, E., I. Karakasiliotis, E. Paximadi, Z. Kyriakopoulou, D. Komiotis, and P. Markoulatos. 2006. Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine. Virus Genes 33:183-191.
18. Domingo, E., and J. J. Holland. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178.
19. El Bassioni, L., I. Barakat, E. Nasr, E. M. deGourville, T. Hovi, S. Blomqvist, C. Burns, M. Stenvik, H. Gary, O. M. Kew, M. A. Pallnsch, and M. H. Wahdan. 2003. Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am. J. Epidemiol. 158:807-815.
20. Fricks, C. E., J. P. Icenogle, and J. M. Hogle. 1985. Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles. J. Virol. 54:856-859.
21. Furione, M., S. Guillot, D. Otelea, J. Balanant, A. Candrea, and R. Crainic. 1993. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196:199-208.
22. Gavrilin, G. V., E. A. Cherkasova, G. Y. Lipskaya, O. M. Kew, and V. I. Agol. 2000. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J. Virol. 74:7381-7390.
23. Georgescu, M. M., J. Balanant, A. Macadam, D. Otelea, M. Combiescu, A. A. Combiescu, R. Crainic, and F. Delpeyroux. 1997. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 71:7758-7768.
24. Georgopoulou, A., P. Markoulatos, N. Spyrou, and N. C. Vamvakopoulos. 2000. Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications. J. Clin. Microbiol. 38:4337-4342.
25. Guillot, S., V. Caro, N. Cuervo, E. Korotkova, M. Combiescu, A. Persu, A. Aubert-Combiescu, F. Delpeyroux, and R. Crainic. 2000. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J. Virol. 74:8434-8443.
26. Harber, J., G. Bernhardt, H. H. Lu, J. Y. Sgro, and E. Wimmer. 1995. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology 214:559-570.
27. He, Y., V. D. Bowman, S. Mueller, C. M. Bator, J. Bella, X. Peng, T. S. Baker, E. Wimmer, R. J. Kuhn, and M. G. Rossmann. 2000. Interaction of the poliovirus receptor with poliovirus. Proc. Natl. Acad. Sci. USA 97:79-84.
28. He, Y., S. Mueller, P. R. Chipman, C. M. Bator, X. Peng, V. D. Bowman, S. Mukhopadhyay, E. Wimmer, R. J. Kuhn, and M. G. Rossmann. 2003. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J. Virol. 77:4827-4835.
29. Hidalgo, S., M. Garcia Erro, D. Cisterna, and M. C. Freire. 2003. Paralytic poliomyelitis caused by vaccine-derived polio virus in an antibody-deficient Argentinean child. Infect. Dis. J. 22:570-572.
30. Hovi, T., M. Stevnik, H. Partanen, and A. Kangas. 2001. Poliovirus surveillance by examining sewage specimens: quantitative recovery of virus after introduction into sewerage at remote upstream location. Epidemiol. Infect. 127:101-106.
31. Hull, H. F., N. A. Ward, J. B. Milstien, and C. de Quadros. 1994. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343:1331-1337.
32. Kew, O. M., V. M. Glasgow, M. Landaverde, C. Burns, J. Shaw, Z. Garib, J. Andre, E. Blackman, C. J. Freeman, J. Jorba, R. Sutter, G. Tambini, L. Venczel, C. Pedreira, F. Laender, H. Shimizu, T. Yoneyama, T. Mijamura, H. van der Avoort, M. S. Oberste, D. Kilpatrick, S. Cochi, M. Pallansch, and C. de Quadros. 2002. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296:356-359.
33. Kew, O. M., R. W. Sutter, E. M. de Gourville, W. R. Dowdle, and M. A. Pallansch. 2005. Vaccine-derived poliovirus and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59:587-635.
34. Kew, O. M., R. W. Sutter, B. K. Nottay, M. J. McDonough, D. R. Prevots, L. Quick, and M. A. Pallansch. 1998. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36:2893-2899.
35. Kumar, S., K. Tamura, and M. Nei. 2004. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 5:150-163.
36. Liang, X., Y. Zhang, W. Xu, N. Wen, S. Zuo, L. A. Lee, and J. Yu. 2006. An outbreak of poliomyelitis caused by type-1 vaccine-derived poliovirus in China. J. Infect. Dis. 194:545-551.
37. Liao, S., and V. Racianello. 1997. Allele-specific adaptation of poliovirus VP1 B-C loop variants target mutant cell receptors. J. Virol. 71:9770-9777.
38. Liu, H. M., D. P. Zheng, L. B. Zhang, M. S. Oberste, O. M. Kew, and M. A. Palansch. 2003. Serial recombination during circulation of type 1 wild-vaccine recombinant poliovirus in China, J. Virol. 77:10994-11005.
39. Liu, H. M., D. P. Zheng, L. B. Zhang, M. S. Oberste, M. A. Palansch, and O. M. Kew. 2000. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J. Virol. 74:11153-11161.
40. Macadam, A. J., G. Ferguson, C. Arnold, and P. D. Minor. 1991. An assembly defect as a result of an attenuating mutation in the capsid proteins of poliovirus type 3 vaccine strain. J. Virol. 65:5225-5231.
41. Manor, Y., R. Handsher, T. Halmut, M. Neuman, A. Bobrov, H. Rudich, A. Vonsoner, L. Shulman, O. Kew, and E. Mendelson. 1999. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J. Clin. Microbiol. 37:1670-1675.
42. Martin, J., G. Dunn, R. Hull, V. Patel, and P. D. Minor. 2000. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74:3001-3010.
43. Martin, J., K. Odoom, G. Tuite, G. Dunn, N. Hopewell, G. Cooper, C. Fitzharris, K. Butler, W. W. Hall, and P. D. Minor. 2004. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78:13839-13847.
44. Minor, P. D. 1990. Antigenic structure of picornavirus. Curr. Top. Microbiol. Immunol. 161:124-154.
45. Minor, P. D., M. Ferguson, D. M. Evans, J. W. Almond, and J. P. Icenogle. 1986. Antigenic structures of polioviruses of serotypes 1, 2 and 3. J. Gen. Virol. 67:1283-1291.
46. Mulders, M. N., G. Y. Lipskaya, H. G. van der Avoort, M. P. Koopmans, O. M. Kew, and A. M. van Loom. 1995. Molecular epidemiology of wild poliovirus 1 in Europe, the Middle East, and the Indian subcontinent. J. Infect. Dis. 171:1399-1405.
47. Mulders, M. N., J. H. J. Reimerink, M. Stevnik, I. Alaeddinoglou, H. G. A. M. van der Avoort, T. Hovi, and M. P. G. Koopmans. 1999. A Sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1. J. Gen. Virol. 80:907-916.
48. Oberste, M. S., K. Maher, M. R. Flemister, G. Marchetti, D. R. Kilpatrick, and M. A. Pallansch. 2000. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J. Clin. Microbiol. 38:1170-1174.
49. Paximadi, E., I. Karakasiliotis, Z. Mamuris, C. Stathopoulos, V. Krikelis, and P. Markoulatos. 2006. Genomic analysis of recombinant Sabin clinical isolates. Virus Genes 32:203-210.
50. Pilipenko, E. V., V. M. Blinov, L. I. Romanova, A. N. Sinyakov, S. V. Maslova, and V. I. Agol. 1989. Conserved structural domains in the 5′-untranslated region of picornaviral genomes: an analysis of the segment controlling translation and neurovirulence. Virology 168:201-209.
51. Rousset, D., M. R. Andrianarivelo, R. Razafindratsimandresy, B. Randriamanalina, S. Guillot, J. Balanant, P. Mauclère, and F. Delpeyroux. 2003. Recombinant vaccine-derived poliovirus in Madagascar. Emerg. Infect. Dis. 9:885-887.
52. Shimizu, H., B. Thorley, F. J. Paladin, K. A. Brussen, V. Stambos, L. Yuen, A. Utama, Y. Tano, M. Arita, H. Yoshida, T. Yoneyama, A. Benegas, S. Roesel, M. Pallansch, O. Kew, and T. Miyamura. 2004. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 78:13512-13521.
53. Shulman, L. M., Y. Manor, R. Handsher, F. Delpeyroux, M. J. McDonough, T. Halmut, I. Silberstein, J. Alfandari, J. Quay, T. Fisher, J. Robinov, O. M. Kew, R. Crainic, and E. Meddelson. 2000. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38:3729-3734.
54. Vinje, J., N. Gregoricus, J. Martin, H. E. Gary, V. M. Cáceres, L. Venczel, A. Macadam, J. G. Dobbins, C. Burns, D. Wait, G. Ko, M. Landaverde, O. M. Kew, and M. D. Sobsey. 2004. Isolation and characterization of circulating type 1 vaccine-derived poliovirus from sewage and stream waters in Hispaniola. J. Infect. Dis. 189:1168-1175.
55. Wien, M. W., S. Curry, D. J. Filman, and J. M. Hogle. 1997. Structural studies of poliovirus mutants that overcome receptor defects. Nat. Struct. Biol. 4:666-674.
56. Wimmer, E., C. U. T. Hellen, and X. Cao. 1993. Genetics of poliovirus. Annu. Rev. Genet. 27:353-436.
57. World Health Organization. 2002. Expanding contributions of the global laboratory network for poliomyelitis eradication. Wkly. Epidemiol. Rec. 77:133-137.
58. World Health Organization. 3 March 2003, posting date. Guidelines for environmental surveillance of poliovirus circulation. World Health Organisation, Geneva, Switzerland. http://www.who.int/vaccines-documents/ DocsPDF03/www737pdf.
59. World Health Organization. 2003. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002-June 2003. Wkly. Epidemiol. Rec. 78:341-348.
60. Yakovenko, M. L., E. A. Cherkasova, G. V. Rezapkin, O. E. Ivanova, A. P. Ivanov, T. P. Eremeeva, O. Y. Baykova, K. M. Chumakov, and V. I. Agol. 2006. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80:2641-2653.
61. Yang, C. F., T. Naguib, S. J. Yang, E. Nasr, J. Jorba, N. Ahmed, R. Campagoli, H. van der Avoort, H. Shimizu, T. Yoneyama, T. Mijamura, M. Pallansch, and O. M. Kew. 2003. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J. Virol. 77:8366-8377.